| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Definium Therapeutics, Inc. (DFTX) has 6 insiders with recent SEC Form 4 filings, including 0 buys and 8 sells. DFTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.10M | $49.37M | -29,208 | |
| Other | 503.3K | $22.62M | -10,035 | |
| Other | 320.6K | $14.41M | -13,008 | |
| CFO | 209.5K | $9.42M | -3,013 | |
| Other | 174.6K | $7.85M | -2,867 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Barrow Robert | Chief Executive Officer | Sell | 29,208 | $45.03 | $1,315,236.24 | -2.6% | - | - | |
| Jun 25, 2026 | Karlin Daniel | Chief Medical Officer | Sell | 10,035 | $45.03 | $451,876.05 | -2.0% | - | - | |
| Jun 25, 2026 | Roberts Brandi | Chief Financial Officer | Sell | 3,013 | $45.03 | $135,675.39 | -1.4% | - | - | |
| Jun 25, 2026 | Wiley Matthew T.82 | Chief Commercial Officer | Sell | 2,867 | $45.03 | $129,101.01 | -1.6% | - | - | |
| Jun 25, 2026 | Sullivan Mark | Chief Legal Officer | Sell | 13,008 | $45.03 | $585,750.24 | -3.9% | - | - | |
| Mar 25, 2026 | Karlin Daniel | Chief Medical Officer | Sell | 8,018 | $18.47 | $148,092.46 | -1.9% | +95.9% | - | |
| Mar 25, 2026 | Barrow Robert | Chief Executive Officer | Sell | 24,431 | $18.47 | $451,240.57 | -3.1% | +95.9% | - | |
| Mar 25, 2026 | Sullivan Mark | Chief Legal Officer | Sell | 10,702 | $18.47 | $197,665.94 | -3.8% | +95.9% | - |